PMC:7068164 / 1455-3317 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"38","span":{"begin":1190,"end":1200},"obj":"Species"},{"id":"39","span":{"begin":1325,"end":1335},"obj":"Species"},{"id":"40","span":{"begin":1377,"end":1388},"obj":"Species"},{"id":"41","span":{"begin":1577,"end":1587},"obj":"Species"},{"id":"42","span":{"begin":204,"end":212},"obj":"Disease"},{"id":"43","span":{"begin":398,"end":406},"obj":"Disease"},{"id":"44","span":{"begin":629,"end":637},"obj":"Disease"},{"id":"45","span":{"begin":869,"end":877},"obj":"Disease"},{"id":"46","span":{"begin":917,"end":936},"obj":"Disease"},{"id":"47","span":{"begin":1138,"end":1158},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:2697049"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:2697049"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:11118"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:2697049"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:C000657245"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:C000657245"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:C000657245"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:C000657245"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D009202"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":204,"end":212},"obj":"Disease"},{"id":"T14","span":{"begin":398,"end":406},"obj":"Disease"},{"id":"T15","span":{"begin":629,"end":637},"obj":"Disease"},{"id":"T16","span":{"begin":869,"end":877},"obj":"Disease"},{"id":"T17","span":{"begin":1138,"end":1146},"obj":"Disease"},{"id":"T18","span":{"begin":1149,"end":1158},"obj":"Disease"},{"id":"T19","span":{"begin":1190,"end":1198},"obj":"Disease"},{"id":"T20","span":{"begin":1325,"end":1333},"obj":"Disease"},{"id":"T21","span":{"begin":1577,"end":1585},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T11","span":{"begin":43,"end":45},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T12","span":{"begin":189,"end":190},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T13","span":{"begin":312,"end":315},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T14","span":{"begin":544,"end":554},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"},{"id":"T15","span":{"begin":845,"end":846},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T16","span":{"begin":980,"end":985},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T17","span":{"begin":1076,"end":1077},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T18","span":{"begin":1097,"end":1098},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T19","span":{"begin":1208,"end":1213},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T20","span":{"begin":1269,"end":1270},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T21","span":{"begin":1289,"end":1290},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T22","span":{"begin":1313,"end":1320},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T23","span":{"begin":1371,"end":1372},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T24","span":{"begin":1373,"end":1376},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9596"},{"id":"T25","span":{"begin":1738,"end":1745},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T26","span":{"begin":1824,"end":1831},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T16","span":{"begin":0,"end":39},"obj":"Sentence"},{"id":"T17","span":{"begin":40,"end":299},"obj":"Sentence"},{"id":"T18","span":{"begin":300,"end":526},"obj":"Sentence"},{"id":"T19","span":{"begin":527,"end":743},"obj":"Sentence"},{"id":"T20","span":{"begin":744,"end":1021},"obj":"Sentence"},{"id":"T21","span":{"begin":1022,"end":1399},"obj":"Sentence"},{"id":"T22","span":{"begin":1400,"end":1755},"obj":"Sentence"},{"id":"T23","span":{"begin":1756,"end":1862},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}

{"project":"2_test","denotations":[{"id":"32156327-32046815-29326676","span":{"begin":1859,"end":1860},"obj":"32046815"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}

{"project":"MyTest","denotations":[{"id":"32156327-32046815-29326676","span":{"begin":1859,"end":1860},"obj":"32046815"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Surveillance in the WHO European Region\nOn 27 January 2020, the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe asked countries to complete a WHO standard COVID-19 case report form for all confirmed and probable cases according to WHO criteria [6-8]. The overall aim of surveillance at this time was to support the global strategy of containment of COVID-19 with rapid identification and follow-up of cases linked to affected countries in order to minimise onward transmission. The surveillance objectives were to: describe the key epidemiological and clinical characteristics of COVID-19 cases detected in Europe; inform country preparedness; and improve further case detection and management. Data collected included demographics, history of recent travel to affected areas, close contact with a probable or confirmed COVID-19 case, underlying conditions, signs and symptoms of disease at onset, type of specimens from which the virus was detected, and clinical outcome. The WHO case definition was adopted for surveillance: a confirmed case was a person with laboratory confirmation of SARS-CoV-2 infection (ECDC recommended two separate SARS-CoV-2 RT-PCR tests), irrespective of clinical signs and symptoms, whereas a probable case was a suspect case for whom testing for SARS-CoV-2 was inconclusive or positive using a pan-coronavirus assay [8]. By 31 January 2020, 47 laboratories in 31 countries, including 38 laboratories in 24 European Union and European Economic Area (EU/EEA) countries, had diagnostic capability for SARS-CoV-2 available (close to 60% of countries in the WHO European Region), with cross-border shipment arrangements in place for many of those lacking domestic testing capacity. The remaining six EU/EEA countries were expected to have diagnostic testing available by mid-February [9]."}